UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  SCHEDULE 13D

                   UNDER THE SECURITIES EXCHANGE ACT OF 1934

                               (AMENDMENT NO. 5)

                              SYNSORB BIOTECH INC.
                                (Name of Issuer)

                           COMMON STOCK, NO PAR VALUE
                         (Title of Class of Securities)

                                  87160V-10-4
                                 (CUSIP Number)

                              GREGORY B. MATTHEWS
                            400,521-3RD AVENUE S.W.
                            CALGARY, ALBERTA T2P 3T3
                                 (403) 263-3653

            (Name, Address and Telephone Number of Person Authorized
                     to Receive Notices and Communications)

                                    COPY TO:

                               WILLIAM L. BOEING
                             HAYNES AND BOONE, LLP
                       1600 N. COLLINS BLVD., SUITE 2000
                            RICHARDSON, TEXAS 75080
                                 (972) 680-7553

                                  MAY 28, 2002
            (Date of Event which Requires Filing of this Statement)


If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box: / /



                                  SCHEDULE 13D

CUSIP NO.  87160V-10-4

(1)  NAME OF REPORTING PERSON
     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     Scout Capital Corp.

(2)  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
                                                (a) / /
                                                (b) /X/

(3)  SEC USE ONLY

(4)  SOURCE OF FUNDS
     WC

(5)  CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
     PURSUANT TO ITEMS 2(d) or 2(e) / /

(6)  CITIZENSHIP OR PLACE OF ORGANIZATION

     Alberta, Canada

                       (7)   SOLE VOTING POWER
NUMBER OF                    537,802
SHARES
BENEFICIALLY           (8)   SHARED VOTING POWER
OWNED BY                     0
EACH
REPORTING              (9)   SOLE DISPOSITIVE POWER
PERSON WITH                  537,802

                       (10)  SHARED DISPOSITIVE POWER
                             0

(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     537,802

(12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
     SHARES [ ]

(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     10.8%

(14) TYPE OF REPORTING PERSON
     CO



        This Amendment No. 5 to Schedule 13D (this "Amendment") amends and
supplements the Schedule 13D filed by Scout Capital Corp. with the Securities
and Exchange Commission ("SEC") on December 31, 2001 relating to the Common
Stock of Synsorb Biotech Inc., as amended by Amendment No. 1 to Schedule 13D
filed with the SEC on January 8, 2002, Amendment No. 2 to Schedule 13D filed
with the SEC on April 23, 2002, Amendment No. 3 to Schedule 13D filed with
the SEC on April 25, 2002, and Amendment No. 4 to Schedule 13D filed with the
SEC on May, 23, 2002 (as previously amended, the "Filing"). Capitalized terms
used herein which are not defined herein have the meanings given to them in
the Filing. The main purpose of this amendment is to amend and restate the
information contained in Item 5 of the Filing. Except as set forth below, all
previous Items of the Filing remain unchanged.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

Item 5 is hereby amended in its entirety to read as follows:

SCOUT CAPITAL CORP.

    (a) Number of Securities Beneficially Owned: 537,802 shares of Common Stock

        Percentage of Class: 10.8%

    (b) Sole Voting Power: 537,802 shares of Common Stock

        Shared Voting Power: 0 shares of Common Stock

        Sole Dispositive Power: 537,802 shares of Common Stock

        Shared Dispositive Power: 0 shares of Common Stock

    (c) The transactions made by Scout in the Common Stock since the date of the
        last amendment to the Filing are detailed on Schedule A hereto, which is
        incorporated herein by this reference.

JIM SILYE

    (a) Number of Securities Beneficially Owned: 12,750 shares of Common Stock

        Percentage of Class: 0.3%

    (b) Sole Voting Power: 12,750 shares of Common Stock

        Shared Voting Power: 0 shares of Common Stock

        Sole Dispositive Power: 12,750 shares of Common Stock

        Shared Dispositive Power: 0 shares of Common Stock

    (c) Mr. Silye has purchased Common Stock since the date of
        the last amendment to the Filing. On May 24, 2002, Mr. Silye
        purchased 12,000 shares of Common Stock at a price of Cdn.$1.25
        through the facilities of the Toronto Stock Exchange.




                                   SIGNATURE

        After reasonable inquiry and to the best of its knowledge and belief,
the undersigned certifies that the information set forth in this Amendment is
true, complete and correct.

                                        SCOUT CAPITAL CORP.

                                        By: /s/ David L. Tonken
                                           -----------------------------------
                                        Name: David L. Tonken
                                        Title: Chief Executive Officer


Date: May 31, 2002



                                   SCHEDULE A

                     SCOUT TRANSACTIONS IN THE COMMON STOCK

TRADES EXECUTED ON THE TORONTO STOCK EXCHANGE:



                        NUMBER OF
        DATE*            SHARES     PRICE (CDN.$)
        -----           ---------   ------------
                              
       5/27/02           31,200        $1.25
       5/28/02           47,700        $1.25


* represents settlement date